Hereditary angioedema, often abbreviated as HAE, is a rare genetic disorder characterized by sudden, severe episodes of swelling in various parts of the body, most commonly affecting the skin, gastrointestinal tract, and airways. Unlike …
Hereditary angioedema stems from mutations in the SERPING1 gene located on chromosome 11, which provides instructions for making C1-esterase inhibitor protein (C1-INH). When a parent carries this mutation, each child has a 50% chance of inheriting it—following an autosomal dominant pattern where only one defective copy is needed to cause disease. About 25% of cases arise from spontaneous new mutations, meaning affected individuals have no family history.
The mutation either reduces the amount of C1-INH protein produced (Type I HAE, accounting for 85% of cases) or creates a dysfunctional version that cannot perform its regulatory role (Type II HAE). A smaller subset, Type III HAE, involves mutations in different genes affecting the same biological pathway. Because this genetic defect is present from conception, individuals carry the predisposition throughout their lives, though the first swelling attack might not occur until childhood, adolescence, or even adulthood.
The inheritance pattern creates multi-generational families affected by HAE, where the disease signature—unpredictable swelling episodes without hives or itching—passes from parent to child with mathematical predictability. Genetic testing can identify carriers before symptoms appear, allowing for early diagnosis and preventive treatment strategies.
The complement system is part of the innate immune response, consisting of over 30 proteins that normally circulate in inactive form until triggered by infection or tissue injury. C1-INH acts as the master brake for the early steps of this cascade, particularly controlling the C1 complex and two related systems—the contact activation pathway and the kallikrein-kinin system. In healthy individuals, C1-INH quickly shuts down these systems after they activate, preventing excessive inflammation.
In HAE patients with deficient or dysfunctional C1-INH, the complement cascade and contact system activate too easily and run too long without proper termination. Even minor triggers—stress, trauma, hormonal changes, or sometimes nothing identifiable—can set off these systems. Without sufficient C1-INH to suppress the activated enzymes, the biochemical reactions continue amplifying themselves in a positive feedback loop.
This uncontrolled cascade particularly affects the contact activation system, where Factor XII, prekallikrein, and high-molecular-weight kininogen interact. The normally brief activation becomes prolonged, with enzymes converting prekallikrein into kallikrein at excessive rates. This enzymatic storm directly leads to the production of the molecule responsible for the actual swelling: bradykinin.
Bradykinin is a small peptide molecule that acts as a powerful signaling molecule, binding to B2 receptors on the surface of blood vessel cells. When the uncontrolled contact system generates excessive kallikrein enzyme, this kallikrein cleaves high-molecular-weight kininogen protein like molecular scissors, releasing bradykinin into surrounding tissues. In HAE patients during an attack, bradykinin levels surge far beyond normal physiological amounts.
This bradykinin flood triggers blood vessel endothelial cells to separate slightly, creating gaps in vessel walls that normally form tight barriers. The molecule also causes vasodilation, widening blood vessels and increasing blood flow to affected areas. Unlike histamine—the culprit in allergic reactions—bradykinin follows a completely different biochemical pathway, which explains why HAE swelling doesn't respond to antihistamines, epinephrine, or corticosteroids that work for allergic conditions.
The location where bradykinin accumulates determines the attack's symptoms: skin swelling when released in subcutaneous tissue, abdominal pain and cramping when flooding intestinal walls, and life-threatening airway obstruction when affecting the throat or tongue. Each attack represents a localized bradykinin storm, with levels gradually declining as the body slowly breaks down the excess peptide through natural degradation processes.
When bradykinin binds to receptors on endothelial cells lining blood vessels, it triggers these cells to contract and pull apart from their neighbors, creating temporary gaps in the vessel wall. Through these gaps, plasma—the liquid component of blood—leaks from capillaries into the interstitial space, the area between cells in tissues. This plasma accumulation physically expands the tissue, creating the characteristic non-pitting edema where pressing on the swollen area leaves no indentation.
In the skin and subcutaneous layers, this fluid accumulation appears as pale, firm swelling without redness or hives—often affecting the face, hands, feet, genitals, or limbs. The swelling expands over hours, typically peaking at 24-36 hours before gradually resolving over 2-5 days as the bradykinin degrades and fluid reabsorbs. In the gastrointestinal tract, the same process causes intestinal wall edema, creating severe cramping abdominal pain, nausea, vomiting, and sometimes diarrhea that can mimic acute surgical emergencies.
The most dangerous swelling occurs in the larynx and tongue, where fluid accumulation in the confined space of the airway progressively narrows the passage for breathing. As edema worsens, it can completely obstruct airflow, creating a medical emergency requiring immediate intervention. Without treatment, laryngeal attacks have historically caused death by asphyxiation in 25-40% of HAE patients over their lifetime.
Modern HAE therapy works by correcting the underlying deficiency or blocking the consequences of excessive bradykinin. C1-esterase inhibitor concentrate, derived from human plasma or produced through recombinant technology, directly replaces the missing or dysfunctional protein in Type I and II HAE. When administered intravenously during an attack, this concentrate immediately begins suppressing the runaway contact system and complement cascade, shutting down further bradykinin production within minutes to hours.
Alternative acute treatments target bradykinin itself rather than preventing its formation. Icatibant is a synthetic molecule that blocks B2 bradykinin receptors, preventing bradykinin already present from triggering vessel leakage—like covering the locks so excess keys cannot open doors. Ecallantide inhibits kallikrein enzyme directly, preventing it from cleaving kininogen to produce more bradykinin. Both approaches interrupt the swelling mechanism at different points in the biochemical pathway.
For long-term prevention, patients can take prophylactic C1-INH concentrate regularly, maintaining adequate levels to prevent attacks before they start. Newer oral medications like berotralstat inhibit plasma kallikrein, reducing baseline bradykinin production. Some patients use attenuated androgens, which increase the liver's production of C1-INH, though these carry significant side effects. These preventive strategies aim to restore the biochemical balance that non-affected individuals maintain naturally, reducing attack frequency from monthly or weekly occurrences to rare breakthrough episodes.